Four other European countries, namely Estonia, Latvia, Lithuania and Luxembourg, have also suspended the use of the AstraZeneca vaccines, which was sent to 17 European countries and contains one million doses.
Following new information received from the Norwegian Medicines Agency on Saturday evening 13 March and following discussions with the Health Products Regulatory Authority (HPRA), the National Immunisation Advisory Committee (NIAC) has recommended that the administration of COVID-19 Vaccine AstraZeneca be temporarily deferred from this morning, Sunday 14 March.
At least two million people were vaccinated on Friday alone, and this ramp up comes at a time when COVID-19 cases are rising across different Indian states after weeks of decline. Denmark was the first to announce suspension, while Italy's pharmaceutical agency on Thursday also ordered a precautionary ban on a particular batch of the AstraZeneca vaccine after what it said were "serious adverse events".
The regional health agency said it will immediately communicate the findings and any recommendations from the World Health Organization (WHO) to regional and worldwide health partners as soon as the body gains a full understanding of the relationship between the deaths and the vaccine.
On Thursday, however, the European Medicines Agency (EMA) said, "There is now no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine".
The WHO had on Friday said there was no reason to stop using the vaccine as several countries suspended the use amid concerns of blood clotting.Читайте также: Amber Alert issued for seven-year-old girl allegedly abducted from Bayfield
The manufacturer and Europe's medicines watchdog have meanwhile insisted that the vaccine is safe.
Geir Bukholm, director of Infection Control and Environmental Health at the Norwegian Institute of Public Health, said that following the decision to suspend the jab, it was now "the Norwegian Medicines Agency's role to follow up on these suspected side effects and take the necessary measures".
He also noted that research on the Oxford-AstraZeneca vaccines, and on the Sinopharm vaccines, has not recorded any adverse events.
"In fact, the reported numbers of these types of events for Covid-19 vaccine AstraZeneca are not greater than the number that would have occurred naturally in the unvaccinated population", a company spokeswoman said.
"The vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing".
"In clinical trials, no trends or patterns were observed with regard to pulmonary embolism, deep vein thrombosis, or events possibly related to thrombocytopenia", they said.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог